Skip to content
My WebMD Sign In, Sign Up

Melanoma/Skin Cancer Health Center

Font Size

Drug Shows Promise Against Advanced Melanoma

In preliminary trial, nivolumab shrank tumors in 30 percent of tough-to-treat patients

continued...

However, although the study participants were described as being "typical" patients with advanced melanoma, the investigation's findings are tempered by the fact that it was not a randomized clinical trial and did not compare the impact of nivolumab directly against the performance of other drugs.

"[But] while this was not a randomized clinical trial, it had a considerable number of patients and the durability of responses is a sign of very promising clinical activity," Sznol said in the news release.

A randomized phase III trial has begun, aimed at confirming these initial findings.

Another expert agreed that the drug shows the promise of immunotherapies in general.

"The results of this study are truly remarkable and demonstrate that immunotherapy truly can make the difference for many melanoma patients," said Dr. Yvonne Saenger, assistant professor of hematology/oncology and dermatology at the Icahn School of Medicine at Mount Sinai Medical Center, New York City.

Saenger, who was not connected to the new study, noted that "earlier immunotherapies, such as interleukin 2 and even Yervoy, can only help a small minority of patients," but nivolumab seems to do much better.

1|2

Today on WebMD

Woman checking out tan lines
SLIDESHOW
Cancer Fighting Foods Slideshow
SLIDESHOW
 
what is your cancer risk
HEALTH CHECK
Could Caffeine Help Fight Skin Cancer
VIDEO
 

12 Ways to Protect Your Skin from Melanoma
ARTICLE
precancerous lesions slideshow
SLIDESHOW
 
Do You Know Your Melanoma ABCs
VIDEO
15 Cancer Symptoms Men Ignore
ARTICLE
 

screening tests for men
SLIDESHOW
Vitamin D
SLIDESHOW
 
Is That Mole Skin Cancer
VIDEO
Brilliant sun rays
Quiz
 

WebMD Special Sections